Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

nce as well as $0.9 million in software depreciation expense for which the software is now fully depreciated and is no longer in use.

Net income for the first quarter of 2009 was $37.5 million, or $0.23 per diluted share, compared with a net loss of $61.9 million in the same period of 2008, or a net loss of $0.42 per diluted share.

Net cash provided by operating activities was $27.7 million for the first quarter of 2009 as compared with net cash used in operating activities of $29.3 million for the first quarter of 2008. In addition to cash provided by operating activities in the three months ended March 31, 2009, we recognized $18.1 million of excess tax benefits from stock-based compensation, which is classified as a financing cash flow. At March 31, 2009, PDL had cash, cash equivalents, short-term investments and restricted cash of $193.2 million, compared with $147.5 million at December 31, 2008.

2009 Dividends

PDL previously announced that it would pay two dividends to its stockholders in 2009 of $0.50 per share. The first dividend, totaling $59.7 million, was paid on April 1, 2009 to all stockholders who owned shares of PDL on March 16, 2009. The second dividend will be paid on October 1, 2009 to stockholders of record on such date as to be determined by the Board of Directors at its June 2009 meeting.

Recent Developments

    -- Elected Frederick Frank and Jody Lindell to the Company's Board of
       Directors in March 2009 and subsequently designated Mr. Frank as Lead
       Director.

    -- As a result of the April 1, 2009 dividend payment, we announced
       An adjustment to the conversion rate for the Company's 2.75%
       Convertible Subordinated Notes due August 16, 2023 (the "2023 Notes").
       The conversion rate, as adjusted, is 123.715 shares of common stock per
       $1,000 principal amount of the 2023 Notes, effective 
'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  UBM Medica US announces ... leading online community to help oncologists and other ... information available regarding the use of targeted therapies ... March is National Kidney Cancer ... effective adjuvant treatment options for renal cell carcinoma ...
(Date:3/5/2015)... RMI specializes in ... conditions such as meniscal tears, ACL injuries, rotator ... pain due to degenerative conditions like osteoarthritis. ... to promote better post-surgical outcomes. , Stemnexa combines ... bone marrow harvesting with two complimentary cellular technologies: ...
(Date:3/4/2015)... BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... consulting firm in the life sciences industry, hired ... Blewitt leads the Cloud Compliance Services and Solutions ... companies utilize cloud based applications while maintaining compliance with ... years, Blewitt has been an accomplished life sciences regulatory ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 ... in Personalized Medicine, is excited to announce the ... Testing to Optimize the Management of Pain”. , ... at Medscape.com for the next year. The focus ... how to recognize inadequate pain treatments, integrate appropriate ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3
... now at 15, SANTA CRUZ, Calif., Sept. 30 ... board and careers tool site for life-science,professionals, Bio Career ... two new schools -- the University of Texas M.,D. ... adding these two schools to the site, we are ...
... Inc. (OTC,Bulletin Board: BTEL) announced results for the year ... $0.23 per diluted share, on revenues of,$11,495,000. This compares ... revenues of $11,233,000 for the prior year. For its ... $0.07 per diluted share, on,revenues of $3,187,000. This compares ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ... U.S. Patent 7,429,485 entitled "Method of Producing ... reassorted reovirus from,an FDA-approved cell line., ... of producing,reassorted reovirus," said Mary Ann Dillahunty, ...
Cached Biology Technology:Two Top-Ranking Schools Join Jobs Board Site 2Biotel Announces Record Revenues and Earnings for Fiscal 2008 2Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent 2
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
(Date:3/2/2015)...   Neurotechnology , a provider of high-precision biometric, ... Software Development Kit (SDK). The SentiGaze algorithm enables ... webcams to track eye movements and generate heatmaps based ... can be used for applications such as analysis of ... SDK can also be used to develop interfaces for ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris Biometrics in ... US, Canada , Japan ... , Middle East , and ... for the period 2013 through 2020. Also, a seven-year historic ... are derived from primary and secondary research. Company profiles are ...
Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11
... the western Antarctic Peninsula since 1850 The ... over the past 50 years (the period of observational ... on the fringes of the peninsula disintegrating. Despite this, ... of days with snowfall has increased by at least ...
... MD The Biophysical Society has announced the speakers for ... of the Biophysical Society and the International Biophysics Congress ... The new and notable symposium highlights the latest and ... and selected by the Societys program committee. The ...
... is a tiny yet insidious waterborne parasite that wreaks ... diarrhea and malnutrition in small children in developing countries, ... compromised patients in the developed world. Cryptosporidium is resistant ... the U.S., which has led to the concern that ...
Cached Biology News:AGU journal highlights -- Jan. 28, 2008 2AGU journal highlights -- Jan. 28, 2008 3AGU journal highlights -- Jan. 28, 2008 4AGU journal highlights -- Jan. 28, 2008 5AGU journal highlights -- Jan. 28, 2008 6Biophysical Society announces new and notable symposium speakers 2Breakthrough research turns the tide on water-borne pathogen 2
... Exonuclease III digests duplex DNA in a ... 5'-overhang or nick, producing stretches of single-stranded ... by Exonuclease III proceeds at a uniform ... the rate of exonucleolytic excision of deoxyribonucleotides ...
... Klenow fragment is a ... coli DNA Polymerase I ... -> 5 exonuclease activity, but ... activity. Klenow retains the polymerization ...
... degrades, as an endoribonuclease, the RNA ... of natural origin, e.g. that of ... e.g. poly(A) x poly(dT). RNase H ... termini. Nearly no activity is detected ...
... E. coli strain containing an overproducing clone of ... the formation of a phosphodiester bond between juxtaposed ... DNA or RNA. It repairs single-stranded nicks in ... join both blunt-end and cohesive-end fragments of duplex ...
Biology Products: